SRC and ovarian carcinoma: Reduction of SRC activity has been shown to increase epithelial appearance [32–34], and since SRC was recently suggested to support adaptive resistance (AR) in ovarian cancer cell lines treated with MEK inhibitors, we sought to investigate a role for SRC activity in the increased sensitivity to ERKi in cells without PTPRS activity.